Quibim has secured $50 million in Series A financing to enhance its AI-driven imaging solutions for precision medicine, supported by notable investors including Asabys Partners and Buenavista Equity Partners.

Information on the Target

Quibim is a pioneering healthtech company specializing in imaging biomarkers for precision medicine. The company aims to provide a comprehensive, non-invasive understanding of every tissue point in the human body at any given moment. Quibim develops foundational AI models that apply advanced analytics to MRI, CT, and PET scans, enabling precise characterization of phenotypes and predictions of patient outcomes in diverse medical fields, including oncology, immunology, neurology, and metabolic disorders.

By developing digital twins at the organ and lesion levels, Quibim is establishing innovative solutions like QP-Brain, QP-Prostate, and QP-Liver. The company's technology is designed to bridge the gap between research, clinical practice, and pharmaceutical development, facilitating improved patient stratification and successful drug development programs.

Industry Overview in Spain

The healthtech sector in Spain has shown robust growth in recent years, driven by advances in technology, increased healthcare spending, and a rising demand for innovative medical solutions. Spain is home to numerous healt